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AbstrAct
Introduction Epidemiological data about diabetes mellitus 
(DM) for sub- Saharan Africa (SSA) are scarce and the utility of 
glycated hemoglobin (HbA1c) to diagnose DM is uncertain in 
African populations with a high proportion of anemia.
Research design and methods In a cross- sectional study, 
age- adjusted prevalence rates and predictors for DM and 
pre- DM were prospectively assessed by HbA1c in a semirural 
walk- in population of Tanzania (n=992). Predictors for DM 
were calculated by logistic regression. Correlations between 
HbA1c, hemoglobin, and blood glucose levels were done by 
Pearson’s correlation.
Results Overall, DM and pre- DM prevalence rates were 
6.8% (95% CI 5.3 to 8.5) and 25% (95% CI 22.8 to 28.3), 
respectively. There was an increase in DM prevalence in 
patients 50–59 (14.9%; 95% CI 9.1 to 22.5), ≥60 years old 
(18.5%; 95% CI 12.2 to 26.2) and in patients with overweight 
(9.3%; 95% CI 5.9 to 13.7), obesity (10.9%; 95% CI 6.9 to 
16) compared with patients 18–29 years old (2.2%; 95% CI 
0.9 to 4.4) (p<0.001) and to normal- weight patients (3.6%; 
95% CI 2.1 to 5.6) (p<0.01), respectively. Age (OR 1.08, 
95% CI 1.05 to 1.12; p<0.001), body mass index (BMI) (OR 
1.10, 95% CI 1.04 to 1.16; p<0.001), and acute infection 
(OR 3.46, 95% CI 1.02 to 10.8; p=0.038) were predictors for 
DM. Comparing patients with a BMI of 20 kg/m2 and a BMI 
of 35 kg/m2, the relative risk for DM increases in average 
by 2.12- fold (range 1.91–2.24) across the age groups. 
Comparing patients 20 years old with patients 70 years old, 
the relative risk for DM increases in average 9.7- fold (range 
8.9–10.4) across the BMI groups. Overall, 333 patients (36%) 
suffered from anemia. Pearson’s correlation coefficients (r) 
between HbA1c and hemoglobin was −0.009 (p=0.779), and 
between HbA1c and fasting blood glucose and random blood 
glucose, it was 0.775 and 0.622, respectively (p<0.001).
Conclusion We observed a high prevalence of DM and 
pre- DM, mainly triggered by increasing age and BMI, and 
provide evidence that HbA1c is suitable to assess DM also in 
populations of SSA with high proportions of anemia.
Trial registration number NCT03458338.
BaCkgRound
For the past few decades, diabetes mellitus (DM) 
and especially type 2 DM became a major global 
public health problem.1 2 Projections for the 
increase of DM prevalence are most dramatic 
for developing countries,1–3 and in particular 
for sub- Saharan Africa (SSA) as consequence 
of the fast demographic and epidemiological 
transition.3 4 Therefore, prevention and strate-
gies against DM are on the current agenda of 
many developing countries including Tanzania 
significance of this study
What is already known about this subject?
 ► Epidemiological data about prevalence rates of dia-
betes mellitus (DM) and prediabetes for sub- Saharan 
Africa are scarce and heterogenic.
 ► The utility of glycated hemoglobin (HbA1c) to diag-
nose DM is uncertain in African populations with a 
high proportion of anemia.
 ► Data about the impact of the pandemic of excess 
body weight and increasing life expectancy on prev-
alence rates of diabetes are scarce in regions of 
sub- Saharan Africa.
What are the new findings?
 ► High overall prevalence rate of diabetes (6.8%) 
and dramatic high of prediabetes (25%) in a sub- 
Saharan Africa population.
 ► The relative risk for DM is nearly 10- fold higher in 
70- year- old than in 20- year- old patients and on av-
erage twofold higher in patients with a body mass 
index (BMI) of 35 kg/m2 compared with patients with 
a BMI of 20 kg/m2.
 ► There is good evidence that HbA1c testing to diag-
nose diabetes can also be applied in African popula-
tions with large proportion of anemia.
How might these results change the focus of 
research or clinical practice?
 ► HbA1c testing could be a useful tool for detecting di-
abetes and prediabetes to enable early intervention 
strategies against the diabetes pandemic.
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and other nations in SSA.4 However, epidemiological data 
about DM prevalence are relatively scarce in the region,3 5 
and most studies in Tanzania were conducted in the 1980s 
and 1990s.5–9 At that time, the DM prevalence in Tanzania 
was estimated at about 2% and impaired glucose tolerance 
at about 8%, with a trend of a higher prevalence in urban 
areas than in rural areas.5–9 The 2016 WHO diabetes profile 
estimates a current DM prevalence of 4.3% in Tanzania 
and illustrates a clear trend of rising numbers for the past 
three decades.10 However, this might not reflect the true 
burden of this chronic disorder, because according to the 
International Diabetes Foundation (IDF) Diabetes Atlas 
from 2017, an estimated majority (>60%) of DM remains 
undiagnosed in SSA. In the light of these trends and projec-
tions, approaches for better screening and early diagnosis 
of DM are most needed.1 11
None of the diagnostic methods for the detection of 
DM is considered a true “gold standard” test.12 13 Conven-
tionally, blood glucose levels are determined in either a 
fasting state or at random, or after the intake of a standard 
portion of glucose.13 In recent years, however, the switch to 
a glycated hemoglobin (HbA1c) based diabetes diagnosis 
found more evidence- based support.13–15 Although HbA1c 
tests are expensive compared with blood glucose measure-
ments,15 Dagogo- Jack et al pointed out in a recent publica-
tion, that HbA1c testing offers “real hope” for research and 
clinical work in SSA, as the less demanding logistics allow 
the test application even in remote parts of the continent.15
However, the diagnosis of DM based on HbA1c also pres-
ents substantial difficulties and needs further exploration. 
The method is based on the entire lifespan of the eryth-
rocyte, and HbA1c is an intergrated index over this time 
period with indication of chronic glycemia rather than 
glycemia at a particular point in time.13 16 Therefore, HbA1c 
can be affected by genetics and hematologic factors.14–16 
The latter aspect may be of particular importance in SSA 
where a high proportion of the population is affected by 
anemia.17 18
The aim of our study was to estimate the prevalence 
rates and predictors of DM and pre- DM based on HbA1c 
measurements, in a semirural walk- in population of 
Tanzania where anemia is highly prevalent.
MeTHods
study population and setting
This is a prospective cross- sectional study performed from 
December 8, 2010 to May 30, 2011. The study population 
covers a walk- in population of the outpatient clinic (OPC) 
of the Bagamoyo District Hospital (BDH) as part of the 
RenalOne study as previously described.17 Briefly, the BDH 
is located in Bagamoyo township and provides care for a 
semirural population. Bagamoyo district had approxi-
mately 300 000 inhabitants in the 2012 census.19 The OPC 
was visited on average by 120 (range 41–164) patients daily 
(survey performed from NH from December 1, 2010 to 
May 31, 2011). For the current study, one consultation 
hour of the general outpatient ward was designated to 
ensure a highly standardized procedure. From the newly 
registered patients of the OPC, 15–20 patients per day were 
consecutively seen, and the call- up of the patients from the 
OPC ward was done through the medical staff, without 
any involvement of the investigators. Pregnant women, 
patients younger than 18 years, and patients neither able 
nor willing to provide informed consent were excluded. All 
participants signed an informed consent form in Swahili. 
For illiterate patients, the consent form has been read and 
the fingerprint of the index finger has been used instead 
of a signature.
Measurements and procedures
In all participants, medical history of DM and the use 
of antidiabetic medication were asked. Body weight 
and height, office blood pressure (BP), heart rate and 
temperature, and demographic data were recorded. BP 
was assessed by a single measurement using a manual 
sphygmomanometer in a sitting position after 5 min at 
rest. HbA1c was measured from capillary blood by using a 
bed- side DCA 2000+ Analyzer (Siemens Healthcare Diag-
nostics). Blood glucose was measured from capillary blood 
using a CONTOUR XT (Bayer Diabetes Care) and time of 
last meal was recorded. Additionally, a blood sample was 
taken for complete blood count and serum creatinine. 
Complete blood count was performed by a Sysmex Xs 800i 
analyser. Serum creatinine was measured using Creatinine 
Jaffe Gen2 reagent on a Cobas Integra 400 plus analyser. 
Estimated glomerular filtration rate (eGFR) was calculated 
using the chronic kidney disease epidemiology collabora-
tion (CKD- EPI) formula.20 After informed consent, HIV- 
screening was done with an immunochromatographic 
test for antibodies to HIV-1 and HIV-2 (test kits: Uni- Gold 
HIV, Trinity Biotech, Ireland; Determine HIV-1/2, Inver-
ness Medical Japan, Japan; SD BIOLINE HIV-1/2 3.0, SD 
Standard Diagnostics, Korea). Malaria was diagnosed based 
on a positive immunochromatographic test (SD BIOLINE 
Malaria Antigen P.f/Pan, SD Standard Diagnostics, Korea). 
All participants were instructed to void a clean- urine spec-
imen. Urine samples were prepared for microscopic anal-
ysis. Albumin- to- creatinine ratio21 was measured using a 
DCA 2000+ analyser (Siemens Healthcare Diagnostics). All 
data were collected in a case report form, translated from 
English to Swahili.
definitions
DM was defined if one of the following criteria was fulfilled: 
a positive history of DM, the use of antidiabetic medication, 
or a HbA1c of ≥6.5% (48 mmol/mol).22 According to the 
American Diabetes Association (ADA), prediabetes (pre- 
DM) was defined if HbA1c≥5.7%–6.49% (39–47 mmol/
mol).23 Impaired glucose metabolism (IGM) was defined 
when either a DM or pre- DM was present in a patient. The 
blood glucose test was considered as fasting blood glucose 
(FBG) measurement, if the time lag between the last meal 
and the enrolment time was ≥8 hours. For the correlation 
with HbA1c values, a FBG measurement ≥7 mmol/L and a 
random blood glucose (RBG) ≥11.1 mmol/L was classified 
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as DM, a FBG≥5.6–6.9 mmol/L and a RBG 7.8–11.1 mmol/L 
as pre- DM, according to the ADA fasting plasma glucose 
classification.21 24 Anemia was defined according to WHO 
classification, if hemoglobin (Hb) was <130.0 g/L in male 
and <120.0 g/L in female patients.25 Acute systemic infec-
tion/inflammation was defined if one of the following 
criteria was fulfilled: body temperature ≥38.5°C (armpit), 
diagnosis of acute malaria, acute tuberculosis, newly diag-
nosed HIV, and urinary tract infection (UTI). UTI was 
defined with a cut- off of >20 leukocytes/high power field 
in urinary sediment.
outcomes
Primary outcomes of the study were DM, pre- DM, and IGM 
prevalence rates and predictors based on HbA1c measure-
ments. Secondary outcome was to explore whether there is 
a relevant interaction between HbA1c and Hb levels.
statistical analyses
Statistical analyses were performed using STATA V.14 
(Stata, College Station, Texas, USA) and R (V.3.2.3).26 
Discrete variables were expressed as counts (percentage), 
and comparison between groups was done with Pearson’s 
χ² test or Fisher’s exact test. Continuous variables were 
expressed as mean±SD if normally distributed or as median 
and range if not normally distributed and comparison 
between groups were done with t- test, Mann- Whitney, or 
Dunn’s test with Holm adjustment as appropriate.
Univariate and multivariate logistic regression was used 
to determine predictors for DM, pre- DM and IGM. Results 
were expressed as OR with 95% confidence intervals (CI). 
To indicate correlations between HbA1c and Hb or blood 
glucose levels Pearson’s correlation tests were performed 
and the Pearson’s correlation coefficient (r) reported. 
P- values of <0.05 were considered as statistically significant.
ResulTs
The initial study population consisted of 1006 patients. Five 
patients aged <18 years had to be excluded. In nine patients, 
no HbA1c was measured; therefore, the DM and pre- DM 
prevalence rates and multivariate analyses for predictors 
were calculated from n=992 patients. Additionally, in 6 
patients age, in three body mass index (BMI), in 19 fasting 
or RBG levels, and in 72 Hb were missing, leading to n=986, 
n=989, n=973, and n=920 available patients for the specific 
analyses, respectively (online supplementary figure S1).
Patient characteristics
Patients characteristics are summarized in table 1. The 
study population consisted of 301 (30%) males and 691 
(70%) females. Overall, median HbA1c was 5.4% (36 
mmol/mol) (range 3.9%–14.0%, 19–130 mmol/mol), 
HbA1c<5.7% (<39 mmol/mol) was seen in 69% (n=682), 
HbA1c 5.7%–6.49% (39–47 mmol/mol) in 25% (n=253), 
and HbA1c≥6.5% (≥48 mmol/mol) in 6% (n=57) of the 
patients. There was no difference by sex in the proportion 
of males and females affected by DM, and pre- DM (p>0.05 
for all). Median age was 36 years (range 18–91 years), 
and patients with DM (54 years (range 19–91 years)) and 
pre- DM (44 years (range 18–89 years)) were older than 
patients without these disorders ((34 (range 18–91 years) 
and 33 years (range 18–84 years), respectively)) (p<0.001). 
BMI was significantly higher in patients with DM (27 kg/
m2 (range 16–48 kg/m2)) and pre- DM (27 kg/m2 (range 
15–47 kg/m2)) than in patients without these disorders 
((24 kg/m2 (range 14–53 kg/m2) and 24 kg/m2 (range 
14–53 kg/m2), respectively)) (p≤0.001). More patients with 
DM (33%; p=0.002) and pre- DM (31%; p<0.001), suffered 
from obesity (BMI ≥30 kg/m2) compared with patients with 
none of these disorders (15%).
Seventy- six patients (8%) were underweight with no 
difference in distribution comparing patients with DM 
and pre- DM with patients without these disorders (p>0.5 
for all). In patients with DM and pre- DM, both systolic 
and diastolic BP were significantly higher than in patients 
without these disorders (p<0.001 for all).
Median hemoglobin was 127 g/L (range 44–220 g/L). 
Overall, anemia was seen in 36% (n=333) and no differ-
ences in distribution were seen between patients with DM 
and without DM/pre- DM (p=0.883). In patients with pre- 
DM, anemia was more frequent compared with patients 
without the disorder (p=0.016). Sixty- three patients (6.2%) 
had HIV without significant difference in distribution 
according to glucose metabolism status. Overall, acute 
infection was seen in 9% (n=89) and more frequent in 
patients with pre- DM than in patients without the disorder 
(13% vs 8%; p=0.025). In patients with DM and in patients 
without DM/pre- DM, the cases of acute infection were 
equally distributed (10% vs 8%; p=0.346). Seventy- six 
patients (8%) had a history of smoking without differences 
in distribution according to glucose metabolism.
Albumin- creatinine ratio was higher in patients with 
DM (14 mg/g (range 2–852 mg/g); p<0.001) and pre- DM 
(7 mg/g (range 2–353 mg/g); p=0.009) than in patients 
with none of these disorders (6 mg/g (range 1–999); 
p≤0.009). Estimated GFR was lower in patients with DM 
(110 mL/min/1.73 m2 (range 47–181)) and pre- DM 
(117 mL/min/1.73 m2 (range 12–202)) than in patients 
without these disorders (130 mL/min/1.73 m2 (range 
5–220); p<0.001 for all)) (table 1).
Prevalence rates of diabetes (dM), prediabetes (pre-dM) and 
impaired glucose metabolism (IgM) across age-groups and 
body mass index (BMI) categories
Overall prevalence rates for DM, pre- DM, and IGM were 
6.8% (95% CI 5.3% to 8.5%), 25% (95% CI 22.8% to 
28.3%), and 32% (95% CI 28.6% to 34.6), respectively 
(table 2). In patients with DM, 85% (57/67) had an 
HbA1c≥6.5% (≥48 mmol/mol). Sixty per cent (40/67) 
had a known history of DM, of whom 57% (23/40) were 
treated by antidiabetics (not shown in table 2).
Prevalence rates increased across age decades (from 
age group 18–29 to ≥60 years) for DM, pre- DM, and IGM 
reaching from 2.2% (95% CI 0.9% to 4.4%) to 18.5% 
(95% CI 12.2% to 26.2%), from 15.6% (95% CI 11.8% 
to 20.0%) to 35.4% (95% CI 28.6% to 45.8%), and from 
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Table 1 Patients characteristics in patients with diabetes and prediabetes
Overall Diabetes
No diabetes+no 
prediabetes P value Prediabetes
No diabetes+no 
prediabetes P value
Overall 992 67 (9%) 678 (91%) 247 (27%) 678 (27%)
Male vs 301 (30%) 20 (9%) 214 (91%) 67 (22%) 234 (78%)
Female 691 (70%) 47 (9%) 464 (91%) 0.928 180 (26%) 511 (74%) 0.205
Age (years) 36 (18–91) 54 (19–91) 34 (18–91) <0.001* 44 (18–89) 33 (18–84) <0.001*
BMI (kg/m2)‡ 23 (14–53) 27(16-48) 24 (14–53) 0.001* 27 (15–47) 24 (14–53) <0.001*
BMI<18.5 76 (8%) 6 (9.0%) 53 (8%) 0.858† 17 (7%) 53 (8%) 0.689†
BMI 18.5–24.9 475 (48%) 17 (25%) 361 (53%) <0.001† 97 (39%) 361 (53%) <0.001†
BMI 25–29.9 236 (24%) 22 (32%) 158 (23%) 0.199† 56 (23%) 158 (23%) 0.789
BMI≥30 202 (20%) 22 (33%) 103 (15%) 0.002† 77 (31%) 103 (15%) <0.001†
BP systolic (mm Hg)§ 120 (70–286) 140 (92–242) 120 (70–286) <0.001* 132 (72–250) 120 (70–286) <0.001*
BP diastolic (mm Hg)¶ 80 (36–150) 90 (42–140) 80 (36–140) <0.001* 80 (48–150) 80 (36–140) <0.001*
HbA1c (%) 5.4 (3.9–14) 7.2 (4.9–14) 5.2 (3.9–5.6) <0.001* 5.9 (5.7–6.4) 5.2 (3.9–5.6) <0.001*
HbA1c<5.7% (<39 mmol/mol) 682 (69%) 3 (5%) 678 (99%) <0.001† 0 (0%) 678 (100%) <0.001†
HbA1c 5.7%–6.49% (39–
47 mmol/mol)
253 (25%) 6 (9%) 0 (0%) <0.001† 247 (100%) 0 (0%) <0.001†
HbA1c≥6.5% (≥48 mmol/mol) 57 (6%) 57 (85%) 0 (0%) <0.001† 0 (0%) 0 (0%) 1.0
Hemoglobin (g/L) 127 (44–220) 132 (68–153) 128 (44–220) 0.309* 124 (60–168) 128 (41–220) 0.001*
Anemia (WHO)** 333 (36%) 18 (33%) 216 (34%) 0.883† 99 (43%) 216 (34%) 0.016†
HIV positive†† 63 (6%) 3 (4%) 23 (6%) 0.789† 18 (7%) 42 (6%) 0.548†
Acute infection‡‡ 89 (9%) 7 (10%) 51 (8%) 0.346† 31 (13%) 51 (8)% 0.025†
History of smoking 76 (8%) 5 (7%) 55 (8%) 1.0† 16 (6%) 55 (8%) 0.486†
ACR mg/g§§ 7 (1–999) 14 (2–852) 6 (1–999) <0.001* 7 (2–353) 6 (1–999) 0.009*
Albuminuria ACR≥30 (mg/g) 126 (13%) 20 (30%) 70 (10%) <0.001* 36 (15%) 70 (10%) 0.080*
eGFR (ml/min/1.73 m2)¶¶ 125 (5–220) 110 (47–181) 130 (5–220) <0.001* 117 (12–202) 130 (5–220) <0.001*
eGFR ≥90 (ml/min/1.73 m2) 854 (88%) 55 (82%) 595 (92%) 0.360† 204 (83%) 595 (88%) 0.051†
eGFR 60–89 (ml/min/1.73 m2) 94 (10%) 9 (13%) 52 (9%) 0.160† 33 (13%) 52 (8%) 0.014†
eGFR <60 (ml/min/1.73 m2) 24 (2%) 3 (4%) 13 (2%) 0.176† 8 (3%) 13 (2%) 0.318†
Data are displayed as counts and (per cent) or median and (range).
*Mann- Whitney- U (rank sum) test.
†Fisher’s exact test.
‡BMI: underweight (BMI<18.5 kg/m2), normal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25–29.9 kg/m2), obesity (BMI≥30 kg/m2) were defined 
according to WHO BMI reference standards.
§BP systolic: blood pressure systolic.
¶BP diastolic: blood pressure diastolic.
**Anemia according to WHO:25 <120g/L female, <130g/L male.
††HIV positive: 42 patients were diagnosed with HIV by testing within the study, 21 patients had a history of HIV, and 19 of them were on 
antiretroviral therapy.
‡‡Acute infection: acute systemic infection/inflammation or possible UTI, that is, body temperature of ≥38.5°C (armpit), acute malaria, acute TB, 
leukocyte count >20/HPF in urinary sediment or newly positive tested HIV cases.
§§ACR: albumin- to- creatinine ratio; Albuminuria: ACR≥30 mg/g.
¶¶eGFR: estimated glomerular filtration rate with CKD- EPI formula.20
BMI, body mass index; CKD- EPI, chronic kidney disease epidemiology collaboration; TB, tuberculosis; UTI, urinary tract infection.
17.8% (95% CI 13.7% to 22.4%) to 53.9% (95% CI 44.9% 
to 62.6%), respectively, (table 2). There was a significant 
increase in DM prevalence rates in patients 50–59 and 
≥60 years old and in pre- DM prevalence rates in patients 
40–49, 50–59, and ≥60 years old compared with patients 
18–29 years old, respectively (p<0.001 for all) (figure 1A).
The prevalence rates across BMI categories are 
depicted in table 2. Prevalence rates in underweight 
patients for DM, pre- DM, and IGM were 7.9% (95% CI 
2.9% to 16.3%), 22.4% (95% CI 13.6% to 23.4%), and 
30.3% (95% CI 20.2% to 41.9%), respectively. Prevalence 
rates increased across BMI categories (from normal 
weight to obesity) for DM, pre- DM, and IGM reaching 
from 3.6% (95% CI 2.1% to 5.6%) to 10.9% (95% CI 
6.9% to 16.0%), from 20.4% (95% CI 16.9% to 24.9%) to 
38.1% (95% CI 31.4% to 45.2%), and from 24% (95% CI 
20.2% to 28.1%) to 49.0% (95% CI 41.9 to 56.1), respec-
tively (table 2).
There was a significant increase in DM prevalence 
rates in patients with overweight (p<0.01) and obesity 
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Table 2 Diabetes, prediabetes, and impaired glucose metabolism prevalence rates across age- groups and BMI categories
N
Diabetes prevalence 
rates
N
Prediabetes 
prevalence rates
N
Impaired glucose 
metabolism prevalence 
rates
% (95% CI) % (95% CI) % (95% CI)
Age category (years)
  18–29 7 2.18 (0.9 to 4.4) 50 15.58 (11.8 to 20.0) 57 17.76 (13.7 to 22.4)
  30–39 7 3.03 (1.2 to 6.1) 42 18.18 (13.8 to 24.2) 49 21.21 (16.1 to 27.0)
  40–49 11 6.01 (3.0 to 10.5) 61 33.33 (27.1 to 41.2) 72 39.34 (32.2 to 46.8)
  50–59 18 14.87 (9.1 to 22.5) 47 38.84 (31.7 to 49.8) 65 53.72 (44.4 to 62.8)
  ≥60 24 18.46 (12.2 to 26.2) 46 35.38 (28.6 to 45.8) 70 53.85 (44.9 to 62.6)
  Overall 67 6.75 (5.3 to 8.5) 246 24.95 (22.8 to 28.3) 314 31.74 (28.7 to 34.6)
BMI (kg/m2)
  <18.5 6 7.89 (2.9 to 16.3) 17 22.37 (13.6 to 33.4) 23 30.26 (20.2- to 41.9)
  18.5–24.9 17 3.58 (2.1 to 5.6) 97 20.42 (16.9 to 24.3) 114 24.00 (20.2 to 28.1)
  25–29.9 22 9.32 (5.9 to 13.7) 56 23.73 (18.5 to 29.6) 78 33.05 (27.1 to 39.4)
  ≥30 22 10.89 (6.9 to 16.0) 77 38.12 (31.4 to 45.2) 99 49.01 (41.9 to 56.1)
  Overall 67 6.77 (5.3 to 8.5) 247 24.97 (22.8 to 28.3) 314 31.75 (28.6 to 34.6)
Impaired glucose metabolism: patients with diabetes and prediabetes; BMI<18.5 kg/m2 underweight, BMI=18.5–24.9 kg/m2 normal weight, 
BMI=25–29.9 kg/m2 overweight, and BMI≥30 kg/m2 obesity.
BMI, body mass index.
(p<0.01), and for pre- DM in obese patients (p<0.001) 
compared with patients with normal weight, respectively 
(figure 1A).
Predictors for diabetes (dM)
In univariate logistic regression analysis, older age (OR 
1.07 per 1 year, 95% CI 1.05 to 1.08; p<0.001), increasing 
BMI (OR 1.10 per 1 kg/m2, 95% CI 1.05 to 1.15; p<0.001), 
increasing BP systolic (OR 1.02 per 1 mm Hg, 95% CI 1.02 
to 1.03; p<0.001), increasing BP diastolic (OR 1.04 per 
1 mm Hg, 95% CI 1.02 to 1.06; p<0.001), and albuminuria 
(OR 4.18, 95% CI 2.17 to 7.78; p<0.001) were statistically 
significant predictors for DM. The OR for the presence 
of DM decreased with increasing eGFR (OR 0.98 per 
1 mL/min/1.73 m2, 95% CI 0.97 to 0.99; p=0.001).
In multivariate logistic regression analysis, older age 
(OR 1.08 per 1 year, 95% CI 1.05 to 1.12; p<0.001), 
increasing BMI (OR 1.10 per 1 kg/m2, 95% CI 1.04 to 
1.16; p<0.001), acute infection (OR 3.46, 95% CI 1.02 to 
10.8; p=0.038) and albuminuria (OR 3.63, 95% CI 1.64 to 
7.83; p=0.001) were statistically significant predictors for 
DM (table 3).
Predictors for prediabetes (pre-dM)
In univariate logistic regression analysis, older age 
(OR 1.04 per 1 year, 95% CI 1.03 to 1.05; p<0.001), 
increasing BMI (OR 1.08 per 1 kg/m2, 95% CI 1.05 to 
1.11; p<0.001), increasing BP systolic (OR 1.01 per 1 mm 
Hg, 95% CI 1.01 to 1.02; p<0.001) and increasing BP 
diastolic (OR 1.03 per 1 mm Hg, 95% CI 1.02 to 1.04; 
p<0.001) were statistically significant predictors for pre- 
DM. An increasing Hb (OR 0.90 per 1 g/dL, 95% CI 
0.83 to 0.97; p=0.004) and the absence of anemia (OR 
0.69, 95% CI 0.50 to 0.94; p=0.019) were associated with 
reduced risk for pre- DM. Further, the OR for the pres-
ence of pre- DM decreased with higher eGFR (OR 0.98 
per 1 mL/min/1.73 m2, 95% CI 0.98 to 0.99; p<0.001) 
(table 3).
In multivariate logistic regression analysis, older age 
(OR 1.03 per 1 year, 95% CI 1.02 to 1.05; p<0.001), 
increasing BMI (OR 1.07 per 1 kg/m2, 95% CI 1.04 to 
1.10; p<0.001) and acute infection (OR 2.79, 95% CI 1.46 
to 5.30; p=0.002) were significant predictors for predia-
betes (table 3).
Predictors for impaired glucose metabolism (IgM)
In univariate logistic regression analysis, older age (OR 
1.04 per 1 year, 95% CI 1.03 to 1.05; p<0.001), increasing 
BMI (OR 1.08 per 1 kg/m2, 95% CI 1.06 to 1.11; p<0.001), 
increasing BP systolic (OR 1.02 per 1 mmHg, 95% CI 1.01 
to 1.02; p<0.001), increasing BP diastolic (OR 1.03 per 
1 mmHg, 95% CI 1.02 to 1.04; p<0.001), acute infection 
(OR 1.63, 95% CI 1.02 to 2.58; p=0.043) and albumin-
uria (OR 1.86, 95% CI 1.23 to 2.80; p=0.004) were statis-
tically significant predictors for IGM. An increasing Hb 
(OR 0.91 per 1 g/dL, 95% CI 0.85 to 0.98; p=0.013) and 
the absence of anemia (OR 0.74, 95% CI 0.56 to 0.99; 
p=0.045) were associated with reduced risk for IGM. 
Further, the OR for the presence of IGM decreased with 
higher eGFR (OR 0.98 per 1 mL/min/1.73 m2, 95% CI 
0.98 to 0.99; p<0.001) (table 3).
In multivariate logistic regression analysis, older age 
(OR 1.04 per 1 year, 95% CI 1.03 to 1.05; p<0.001), 
increasing BMI (OR 1.07 per 1 kg/m2, 95% CI 1.04 to 
1.10; p<0.001) and acute infection (OR 2.99, 95% CI 1.62 
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Figure 1 Effect of age and BMI on estimated prevalence and estimated risk for diabetes mellitus. (A) Effect of age and BMI 
on estimated prevalence; reference group 18–29 years, ***p<0.001, n.s.: non significant; reference group BMI 18.5-24.9 kg/
m2, **p<0.01, ***p<0.001, n.s.: non significant. (B) Estimated risk for diabetes mellitus stratified by BMI across age groups and 
stratified by age across BMI categories. BMI<18.5 kg/m2 underweight, BMI=18.5–24.9 kg/m2 normal weight, BMI=25–29.9 kg/
m2 overweight, and BMI≥30 kg/m2 obesity. BMI, body mass index.
to 5.54; p<0.001) were significant predictors for IGM 
(table 3).
effect of age and body mass index (BMI) on the estimated 
risk for diabetes
Figure 1B illustrates the effect of age and BMI on the esti-
mated risk of diabetes. Comparing patients with a BMI of 
20 kg/m2 and a BMI of 35 kg/m2, the relative risk for DM 
increases in average by 2.12- fold (range 1.91–2.24) across 
the age groups. Comparing patients 20 years old with 
patients 70 years old, the relative risk for DM increases in 
average 9.7- fold (range 8.9–10.4) across the BMI groups 
(online supplementary table S1).
Correlation of glycated hemoglobin (Hba1c) and hemoglobin 
(Hb) levels
Overall, mean values of HbA1c did not differ in patients 
with (5.58% (37 mmol/mol); 95% CI 5.5% to 5.7% 
(37–39 mmol/mol)) and without anemia (5.57% (37 
mmol/mol); 95% CI 5.5% to 5.7% (37–39 mmol/mol); 
p=0.872). Further, mean values of HbA1c values≥6.5% 
(≥48 mmol/mol) (n=47) did not differ in patients 
with (8.88% (74 mmol/mol); 95% CI 7.2% to 10.5% 
(55–91 mmol/mol)) and without anemia (9.03% (75 
mmol/mol); 95% CI 8.1% to 10.0% (65–86 mmol/mol); 
p=0.859). In males (all), mean HbA1c value was higher 
in males with (5.88% (41 mmol/mol); 95% CI 5.4% to 
6.3% (36–45 mmol/mol)) compared with males without 
anemia (5.48% (36 mmol/mol); 95% CI 5.4% to 5.6% 
(36–38 mmol/mol); p=0.024). There was no significant 
difference in females with and without anemia in mean 
HbA1c value (p=0.28) (online supplementary table S2).
Pearson’s correlation between HbA1c levels and hemo-
globin levels is depicted in figure 2. For the whole popu-
lation, the Pearson’s correlation coefficient between 
HbA1c and Hb levels was r=−0.009 (p=0.779); in males, 
it was r=−0.132 (p=0.028); in females, it was r=0.062 
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Figure 2 Pearson’s correlation of HbA1c with hemoglobin and blood glucose values. (A) Pearson’s correlation of HbA1c 
with hemoglobin; r: Pearson’s correlation coefficient (r); black solid line: fitted values of correlation between HbA1c (%) and 
hemoglobin (g/L); black thin dashed line: HbA1c 6.5% (cut- off to diagnose DM);4 vertical dashed lines with dots: WHO anemia 
cut- off levels for males (130 g/L);25 vertical dashed lines without dots: WHO anemia cut- off levels for females (120 g/L);25 
missing hemoglobin: *n=12, †n=17, ‡n=19. (B) Pearson’s correlation of HbA1c and blood glucose values; black solid line: fitted 
values of correlation between HbA1c (%) and blood glucose (mmol/L). DM, diabetes; FBG, fasting blood glucose; pre- DM, 
prediabetes; RBG, random blood glucose.
(p=0.114); in the subgroup of patients with DM, it was 
r=0.153 (p=0.264), with pre- DM, it was r=0.026 (p=0.700), 
and with fasting blood glucose (FBG), it was r=−0.012 
(p=0.862) (figure 2A).
Correlation of glycated hemoglobin (Hba1c) and blood 
glucose values
In 23% (n=229) of the population FBG was measured, 
the Pearson’s correlation coefficient between HbA1c 
and FBG was r=0.775 (p<0.001). In the remaining 
patients (n=744), a RBG was measured and the Pearson’s 
correlation coefficient for HbA1c and RBG was r=0.662 
(p<0.001). The correlation coefficient between HbA1c 
and all blood glucose values (n=973) was r=0.676 
(p<0.001) (figure 2B).
Correlation of glycated hemoglobin (Hba1c) and blood 
glucose values in different stages of glucose metabolism
In patients with both HbA1c and BG (FBG or RBG) values 
in the diabetic range (n=24), median BG was numer-
ically higher (14.7 mmol/L; inter quartile range (IQR) 
6.4 mmol/L) than in patients in whom only BG (n=6) 
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was in the diabetic range (9.8 mmol/L; IQR 4.2 mmol/L) 
(p=0.443). In patients with only HbA1c in the diabetic 
range (n=33), median BG was lower (5.8 mmol/L; IQR 
1.5 mmol/L) than in patients with both HbA1c and BG 
in the diabetic range (14.7 mmol/L; IQR 6.4 mmol/L) 
(p<0.001), but higher than in patients without IGM 
(4.7 mmol/L; IQR 1.0 mmol/L) (p<0.001) (figure 3A 
and included table a).
In patients with both HbA1c and BG (FBG or RBG) 
values in the diabetic range (n=24), median HbA1c was 
numerically higher (11.2%; IQR 4.9% (99 mmol/mol; 
IQR 30 mmol/mol)) than in patients in whom only 
HbA1c (n=33) was in the diabetic range (6.8%, IQR 
1.2% (51 mmol/mol)) (p<0.344). In patients with only 
BG in the diabetic range (n=6), median HbA1c was lower 
(5.7%; IQR 0.9% (39 mmol/mol)) than in patients with 
both HbA1c and BG in the diabetic range (11.2%; IQR 
4.9% (99 mmol/mol; IQR 30 mmol/mol)) (p<0.001), but 
higher than in patients without IGM (5.2%; IQR 0.5% (33 
mmol/mol)) (p<0.001) (figure 3B and included table b).
The corresponding results in patients with values in the 
prediabetic range and in patients with values in the range 
of IGM are depicted in figure 3C F and in the included 
tables c–f.
dIsCussIon
In our study 31.8% of the patients had an IGM, which is 
composed of a high overall DM prevalence of 6.8% and 
a dramatic high pre- DM prevalence of 25%. Prevalence 
rates and risk for DM were strongly dependent on BMI 
and age. In addition, we provide further evidence that 
HbA1c testing appears suitable for the diagnosis of DM 
in black African populations, even if anemia is highly 
prevalent.
The observed overall DM prevalence rate of 6.8% was 
as high as the age adjusted DM prevalence rate reported 
for Europe by the IDF in 20174 and is advancing towards 
prevalence rates reported in recent years for the USA 
(9.4%) and Canada (7.4%).4 27
However, in SSA, data remain scarce for many countries 
and heterogenic throughout,4 especially due to differ-
ences in life and demographic conditions, and diagnos-
tics standards.6 7 9 11 28 29 Thirty years ago, the estimated 
DM prevalence was as low as 1% in rural Tanzania.7 As 
observed in our study in the following years, a trend of 
rising numbers was seen and DM prevalence rates around 
5%–7% were reported in populations with proceeding 
age from Tanzania and its neighboring countries Kenya 
and Uganda.9 11 28 29
Little is still known about the frequency of pre- DM in 
populations from SSA. Reported prevalence rates vary 
between 3% and 25%.11 28 30 31 In recently published 
nation- wide, population- based surveys from Kenya 
and Uganda, a pre- DM prevalence of around 3% was 
reported.30 31 Findings from surveys in northern Tanzania 
(16%) and Uganda (20%) are reporting larger rates, 
depending on the population and methodology.11 28 We 
found a very high pre- DM prevalence of 25%. The risk to 
suffer from IGM might be higher in a walk- in population 
than in a general population, for which reason the data 
are not generalizable. However, as pre- DM is a strong risk 
factor for the development of DM, the finding is alarming 
despite this limitation.21 32
In our population, there was an impressively strong 
rise in DM prevalence with increasing age and BMI, espe-
cially after the age of 50 years and a BMI above 25 kg/m2. 
For pre- DM, the same observation was made for patients 
a decade younger with a prevalence of more than 30% 
beginning at the age of 40 years. This finding supports 
the observation that pre- DM is a forerunner for DM.21 32
The relevance of age and BMI is also reflected by the 
increasing relative risk for DM, which is nearly 10- fold 
higher in 70- year- old than in 20- year- old patients and 
on average twofold higher, if a patient presents a BMI 
of 35 kg/m2 compared with a patient with BMI 20 kg/
m2. This is of great relevance in the setting of SSA where 
the pandemic of excess bodyweight remains ongoing 
and life expectancy is increasing steadily over the last 
two decades, reaching more than 65 years in Tanzania in 
2016.1 33 However, the populations in developing regions 
are exposed to both extremes, obesity and underweight, 
as can also be observed in our population with a preva-
lence of almost 10% underweight patients. In the litera-
ture, an association between malnutrition and diabetes is 
discussed, which is also referred to as malnutrition- related 
or malnutrition- modulated diabetes.9 15 33 34 However, the 
pathogenesis is not very well understood and epidemi-
ological data are still missing.34 In our data, a J- shaped 
distribution of DM rates along the BMI scale could be 
observed, which supports the existence of the entity of a 
malnutrition- related diabetes. Unfortunately, we have no 
data on the causes of underweight in our population that 
could help to better understand the underlying patho-
physiological processes.
Besides increasing age and BMI, acute infection was a 
further predictor for IGM. This is in line with the known 
bidirectional interaction between infectious disease and 
IGM.35 36 DM is associated with immune- dysregulation 
and increased susceptibility to infections,36 and infectious 
conditions contribute to the dysregulation of the glucose 
metabolism.37 Therefore, particularly in SSA, where 
endemic infectious diseases remain highly prevalent,38 39 
the growing DM pandemic will further contribute to the 
“double burden of disease” and take its toll on the popu-
lations well- being and the health systems.17 37 40
Testing HbA1c offers advantages and conveniences, 
such as preanalytical stability, better reproducibility and 
no requirement for fasting.13 41 A quick point- of- care test 
without fasting requirements might be very useful in the 
setting of semirural SSA.33
A decade ago, an expert panel reported that HbA1c 
testing for DM diagnosis is limited in patients with 
anemia,42 due to a more rapid erythrocyte turnover,16 42 
which lowers the non- enzymatic glycosylation of Hb and 
decreases the HbA1c level in such patients.16 43 In our 
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Figure 3 Venn diagram of median blood glucose and median HbA1c values in ranges of diabetes, prediabetes, and 
impaired glucose metabolism. Venn diagram: Median blood glucose levels (A,C,E) and median HbA1c levels (B,D,F) 
stratified by concordance and discordance between HbA1c levels and blood glucose levels in patients with values in 
diabetic range (HbA1c≥6.5% or FBG≥7 mmol/L or RBG≥11.1 mmol/L), in patients with values in prediabetic range (HbA1c 
5.7%–6.49% or FBG 5.6–6.9 mmol/L or RBG 7.8–11.1 mmol/L), and in patients with values in the range of impaired glucose 
metabolism (HbA1c≥5.7% or FBG≥5.6 mmol/L or RBG≥7.8 mmol/L) and no IGM (HbA1c<5.7% and FBG<5.6 mmol/L or 
RBG<7.8 mmol/L).21 24 Tables a–f: corresponding tables to Venn diagrams A–F. P values according to Dunn’s test with Holm 
adjustment for pairwise comparison. BG, blood glucose; FBG, fasting blood glucose; HbA1c, glycated hemoglobin; IGM, 
impaired glucose metabolism; IQR: interquartile range (Q3–Q1); RBG, random blood glucose.
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analyses, there was no evidence of a relevant interac-
tion in the whole population as well as in the explored 
subgroups between HbA1c and Hb values. Only in the 
subgroup of men a statistically significant correlation 
was observed. However, the correlation was very weak, 
and—other than one would expect—reversed, that is, 
men with anemia had higher HbA1c levels than men 
without anemia. This is in line with findings from data 
analyzed from the National Health and Nutrition Exam-
ination Survey (NHANES) 1999–2002, where only 
marginal effects between HbA1c concentration and Hb 
were observed.43
We could further show that there was a strong correla-
tion and a clear “dose dependent” relationship between 
HbA1c levels and FBG as well as RBG values. The highest 
HbA1c values were observed in patients who had also 
FBG or RBG values in the diabetic range. In discordant 
pairs in which only HbA1c was in the diabetic range, FBG 
and RBG were lower, but still clearly higher than in the 
population with normal HbA1c values. Vice versa, in the 
few cases in which only FBG or RBG were in the diabetic 
range and HbA1c values were not, the HbA1c levels were 
higher than the values of the normal population. This 
observation was also consistent in the prediabetic states 
and overall for all patients with IGM, even if it did not 
always reach the level of significance due to the small 
number of cases. The clear positive relationship between 
HbA1c and FBG and even RBG in a cross- sectional setting 
is astonishing, because the strength of HbA1c measure-
ments lies in the reflection of glucose metabolism over 
the past few months and not in the correlation with 
random single BG measurements. The results underline 
that HbA1c is very valid and reliable to detect a disturbed 
glucose balance even in populations with a high propor-
tion of anemia, such as those in SSA. Our findings are 
further supported by a recently published study, which 
found similar age- standardized DM prevalence estimates 
based on HbA1c, oral glucose tolerance test, and FBG in 
an urban black South African population.14 However, in 
this study, data on Hb levels and their impact on HbA1c 
levels were not explored.14
We face several limitations in our study. The IGM preva-
lence might be overestimated due to a single point HbA1c 
measurement.41 The generalizability of the results is 
limited, because the sample represents a population from 
the OPC and not the general population. Our data do not 
allow drawing definitive conclusions about causality and 
about the progression from pre- DM toward DM. Finally, we 
lack data to describe the underlying causes of anemia and 
their specific impact on HbA1c levels.
To conclude, by means of a semirural population from 
Tanzania, we confirm the trend of rising prevalence and 
the ongoing spread of the DM pandemic in SSA. Partic-
ularly, the relationship of increasing age and BMI and 
the very high rate of pre- DM is supporting the projection 
that the DM pandemic will continue. Therefore, strat-
egies like “The 2016 Dar es Salaam—Call to Action on 
Diabetes and other non- communicable diseases” plan are 
urgently needed in SSA and put to practice.44 Finally, our 
data present evidence for the usefulness of HbA1c testing 
in populations from SSA affected by a large proportion of 
anemia. In a next step, intervention studies are needed to 
oppose the DM pandemic in SSA. Moreover, such a frame 
would offer the in- depth exploration and utility of HbA1c 
as longitudinal and monitoring tool in populations of SSA.
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